These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
230 related items for PubMed ID: 18843015
1. Progestagens use before menopause and breast cancer risk according to histology and hormone receptors. Fabre A, Fournier A, Mesrine S, Gompel A, Desreux J, Berrino F, Boutron-Ruault MC, Romieu I, Clavel-Chapelon F. Cancer Epidemiol Biomarkers Prev; 2008 Oct; 17(10):2723-8. PubMed ID: 18843015 [Abstract] [Full Text] [Related]
2. Risk factors for hormone receptor-defined breast cancer in postmenopausal women. Rosenberg LU, Einarsdóttir K, Friman EI, Wedrén S, Dickman PW, Hall P, Magnusson C. Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2482-8. PubMed ID: 17164374 [Abstract] [Full Text] [Related]
3. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Grann VR, Troxel AB, Zojwalla NJ, Jacobson JS, Hershman D, Neugut AI. Cancer; 2005 Jun 01; 103(11):2241-51. PubMed ID: 15844176 [Abstract] [Full Text] [Related]
4. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. Fournier A, Fabre A, Mesrine S, Boutron-Ruault MC, Berrino F, Clavel-Chapelon F. J Clin Oncol; 2008 Mar 10; 26(8):1260-8. PubMed ID: 18323549 [Abstract] [Full Text] [Related]
5. Predicting risk of breast cancer in postmenopausal women by hormone receptor status. Chlebowski RT, Anderson GL, Lane DS, Aragaki AK, Rohan T, Yasmeen S, Sarto G, Rosenberg CA, Hubbell FA, Women's Health Initiative Investigators. J Natl Cancer Inst; 2007 Nov 21; 99(22):1695-705. PubMed ID: 18000216 [Abstract] [Full Text] [Related]
6. Relationship between histamine2-receptor antagonist medications and risk of invasive breast cancer. Mathes RW, Malone KE, Daling JR, Porter PL, Li CI. Cancer Epidemiol Biomarkers Prev; 2008 Jan 21; 17(1):67-72. PubMed ID: 18199712 [Abstract] [Full Text] [Related]
7. Impact of hormone replacement therapy on the histologic subtype of breast cancer. Zanetti-Dällenbach RA, Krause EM, Lapaire O, Gueth U, Holzgreve W, Wight E. Arch Gynecol Obstet; 2008 Nov 21; 278(5):443-9. PubMed ID: 18335229 [Abstract] [Full Text] [Related]
8. Unopposed estrogen therapy and the risk of invasive breast cancer. Chen WY, Manson JE, Hankinson SE, Rosner B, Holmes MD, Willett WC, Colditz GA. Arch Intern Med; 2006 May 08; 166(9):1027-32. PubMed ID: 16682578 [Abstract] [Full Text] [Related]
9. Serum cholesterol level, use of a cholesterol-lowering drug, and breast cancer: results from the prospective E3N cohort. Fagherazzi G, Fabre A, Boutron-Ruault MC, Clavel-Chapelon F. Eur J Cancer Prev; 2010 Mar 08; 19(2):120-5. PubMed ID: 20042864 [Abstract] [Full Text] [Related]
10. Hip circumference is associated with the risk of premenopausal ER-/PR- breast cancer. Fagherazzi G, Chabbert-Buffet N, Fabre A, Guillas G, Boutron-Ruault MC, Mesrine S, Clavel-Chapelon F. Int J Obes (Lond); 2012 Mar 08; 36(3):431-9. PubMed ID: 21427693 [Abstract] [Full Text] [Related]
11. A French national survey on infiltrating breast cancer: analysis of clinico-pathological features and treatment modalities in 1159 patients. Cutuli B, Cottu PH, Guastalla JP, Mechin H, Costa A, Jourdan R. Breast Cancer Res Treat; 2006 Jan 08; 95(1):55-64. PubMed ID: 16261401 [Abstract] [Full Text] [Related]
12. Alcohol and breast cancer risk defined by estrogen and progesterone receptor status: a case-control study. Deandrea S, Talamini R, Foschi R, Montella M, Dal Maso L, Falcini F, La Vecchia C, Franceschi S, Negri E. Cancer Epidemiol Biomarkers Prev; 2008 Aug 08; 17(8):2025-8. PubMed ID: 18708394 [Abstract] [Full Text] [Related]
13. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Olsson HL, Ingvar C, Bladström A. Cancer; 2003 Mar 15; 97(6):1387-92. PubMed ID: 12627501 [Abstract] [Full Text] [Related]
14. A prospective study of smoking and risk of breast cancer in young adult women. Al-Delaimy WK, Cho E, Chen WY, Colditz G, Willet WC. Cancer Epidemiol Biomarkers Prev; 2004 Mar 15; 13(3):398-404. PubMed ID: 15006915 [Abstract] [Full Text] [Related]
15. Plasma prolactin concentrations and risk of postmenopausal breast cancer. Tworoger SS, Eliassen AH, Rosner B, Sluss P, Hankinson SE. Cancer Res; 2004 Sep 15; 64(18):6814-9. PubMed ID: 15375001 [Abstract] [Full Text] [Related]
16. Hormone therapy and breast cancer: what factors modify the association? Gertig DM, Fletcher AS, English DR, Macinnis RJ, Hopper JL, Giles GG. Menopause; 2006 Sep 15; 13(2):178-84. PubMed ID: 16645531 [Abstract] [Full Text] [Related]
17. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas. Wei B, Wang J, Bourne P, Yang Q, Hicks D, Bu H, Tang P. Hum Pathol; 2008 Dec 15; 39(12):1809-15. PubMed ID: 18715613 [Abstract] [Full Text] [Related]
18. Serum high-density lipoprotein cholesterol and breast cancer risk by menopausal status, body mass index, and hormonal receptor in Korea. Kim Y, Park SK, Han W, Kim DH, Hong YC, Ha EH, Ahn SH, Noh DY, Kang D, Yoo KY. Cancer Epidemiol Biomarkers Prev; 2009 Feb 15; 18(2):508-15. PubMed ID: 19190159 [Abstract] [Full Text] [Related]
19. Progestagen-only treatment before menopause: increased risk of breast cancer. Prescrire Int; 2008 Dec 15; 17(98):243. PubMed ID: 19422175 [Abstract] [Full Text] [Related]
20. Dietary mushroom intake and the risk of breast cancer based on hormone receptor status. Shin A, Kim J, Lim SY, Kim G, Sung MK, Lee ES, Ro J. Nutr Cancer; 2010 Dec 15; 62(4):476-83. PubMed ID: 20432168 [Abstract] [Full Text] [Related] Page: [Next] [New Search]